Aclaris Therapeutics Statistics
Share Statistics
Aclaris Therapeutics has 107.02M shares outstanding. The number of shares has increased by 0.71% in one year.
| Shares Outstanding | 107.02M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.12% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 89.49M |
| Failed to Deliver (FTD) Shares | 386 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 3.16M, so 4.43% of the outstanding shares have been sold short.
| Short Interest | 3.16M |
| Short % of Shares Out | 4.43% |
| Short % of Float | 5.28% |
| Short Ratio (days to cover) | 0.6 |
Valuation Ratios
The PE ratio is -0.83 and the forward PE ratio is -4.41.
| PE Ratio | -0.83 |
| Forward PE | -4.41 |
| PS Ratio | 2.35 |
| Forward PS | 32.2 |
| PB Ratio | 0.47 |
| P/FCF Ratio | -0.92 |
| PEG Ratio | n/a |
Enterprise Valuation
Aclaris Therapeutics Inc. has an Enterprise Value (EV) of 33.85M.
| EV / Earnings | -0.38 |
| EV / Sales | 1.08 |
| EV / EBITDA | -0.29 |
| EV / EBIT | -0.35 |
| EV / FCF | -0.43 |
Financial Position
The company has a current ratio of 4.16, with a Debt / Equity ratio of 0.
| Current Ratio | 4.16 |
| Quick Ratio | 4.16 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.56% and return on capital (ROIC) is -61.52%.
| Return on Equity (ROE) | -0.56% |
| Return on Assets (ROA) | -0.45% |
| Return on Capital (ROIC) | -61.52% |
| Revenue Per Employee | 363.36K |
| Profits Per Employee | -1.03M |
| Employee Count | 86 |
| Asset Turnover | 0.16 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -367.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 115.52% in the last 52 weeks. The beta is 0.12, so Aclaris Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.12 |
| 52-Week Price Change | 115.52% |
| 50-Day Moving Average | 3.02 |
| 200-Day Moving Average | 1.67 |
| Relative Strength Index (RSI) | 39.91 |
| Average Volume (20 Days) | 2.59M |
Income Statement
In the last 12 months, Aclaris Therapeutics had revenue of 31.25M and earned -88.48M in profits. Earnings per share was -1.27.
| Revenue | 31.25M |
| Gross Profit | 13.17M |
| Operating Income | -97.36M |
| Net Income | -88.48M |
| EBITDA | -117.56M |
| EBIT | -97.36M |
| Earnings Per Share (EPS) | -1.27 |
Balance Sheet
The company has 39.88M in cash and 426.00K in debt, giving a net cash position of 39.45M.
| Cash & Cash Equivalents | 39.88M |
| Total Debt | 426.00K |
| Net Cash | 39.45M |
| Retained Earnings | -770.80M |
| Total Assets | 182.39M |
| Working Capital | 113.51M |
Cash Flow
In the last 12 months, operating cash flow was -78.33M and capital expenditures -1.31M, giving a free cash flow of -79.63M.
| Operating Cash Flow | -78.33M |
| Capital Expenditures | -1.31M |
| Free Cash Flow | -79.63M |
| FCF Per Share | -1.14 |
Margins
Gross margin is 42.14%, with operating and profit margins of -311.55% and -283.15%.
| Gross Margin | 42.14% |
| Operating Margin | -311.55% |
| Pretax Margin | -284.32% |
| Profit Margin | -283.15% |
| EBITDA Margin | -376.22% |
| EBIT Margin | -311.55% |
| FCF Margin | -254.84% |
Dividends & Yields
ACRS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -50.8% |
| FCF Yield | -29.82% |
Analyst Forecast
The average price target for ACRS is $8, which is 220% higher than the current price. The consensus rating is "Buy".
| Price Target | $8 |
| Price Target Difference | 220% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -4.35 |
| Piotroski F-Score | 3 |